Doylestown, Pennsylvania, executive, Terrell (“Terry”) Herring directs the commercial efforts for the Mission Family of Companies and guides diverse subsidiaries such as BioComp Pharmaceuticals and Alamo Pharma Services. Terrell Herring’s company purchased Miami-based ProSolus Pharma in 2015, with the transaction adding significantly to Mission's overall manufacturing supply capacities. 

The firm offers leading-edge transdermal drug manufacturing and development solutions that are characterized as efficient and convenient. In particular, it has created innovative drug delivery products that enable treatment for a variety of conditions through patches placed on the skin. 

The transdermal solutions are characterized as high-barrier-to-entry and provide benefits such as superior adhesion on the skin and reliability in reproducible blood levels. Small and non-irritating, the patches integrate the latest delivery technologies to achieve top-tier results in conformance with care provider needs. Advantages of the patches versus pills include minimizing the chance of abuse and diversion and increasing compliance rates. Because medications pass directly into the bloodstream, less concentrated doses are typically required.